How GLP-1 Shortages Are (and Aren't) Resolved in 2026

Last Updated: January 2026

The FDA officially removed semaglutide from its drug shortage list in February 2025, marking the end of a three-year supply crisis that left 68% of U.S. patients reporting difficulty accessing prescribed GLP-1 medications at some point during 2023-2024, according to Kaiser Family Foundation survey data. But "resolved" is doing heavy lifting here. The regulatory declaration didn't magically conjure adequate supply—it triggered a 60-day countdown that ended compounding pharmacy access for millions who'd turned to $200-per-month alternatives when Novo Nordisk and Eli Lilly couldn't keep up with demand.

Tirzepatide followed a similar trajectory, exiting the shortage list in October 2024 with transition periods ending February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. The FDA's position: manufacturer capacity has sufficiently recovered. The patient experience: not quite.

Manufacturing Capacity vs. Market Reality

Novo Nordisk invested $6.8 billion in U.S. manufacturing expansion between 2022-2025, adding three production lines in North Carolina specifically for semaglutide fill-finish operations. Eli Lilly committed $5.3 billion to new facilities in Indiana and Ireland, projecting 400% capacity increase for tirzepatide by end of 2025. Those numbers sound impressive until you contextualize demand.

U.S. prescriptions for GLP-1 agonists hit 9.4 million in Q4 2025, up from 3.2 million in Q4 2022—a 194% increase in three years. Manufacturer capacity grew roughly 180% in that same window. The math doesn't add up to "abundance."

What actually happened: manufacturers achieved consistent production of branded products at most dose strengths. Wegovy 2.4mg pens? Generally available. Zepbound 15mg? Usually in stock. But starter doses—the 0.25mg and 0.5mg semaglutide pens that every new patient needs—remain sporadically unavailable at major pharmacy chains. Walgreens reported 22% fill rate delays for starter doses in December 2025 internal data obtained by Reuters. CVS wouldn't provide specific numbers but acknowledged "intermittent availability challenges at lower dose strengths."

The FDA's shortage determination focuses on whether manufacturers can meet "medically necessary demand." That's a regulatory term of art that doesn't account for the 12.6 million Americans the CDC estimates could clinically benefit from GLP-1 therapy based on BMI and comorbidity criteria. It means: can existing patients generally get their prescriptions filled? Mostly yes. Can everyone who needs these medications access them? Absolutely not.

The Compounding Crackdown

When the FDA yanked compounding permissions, it eliminated a market serving an estimated 2-3 million patients, per Outsourcing Facilities Association figures. Those patients faced a choice: pay $900-1,400 monthly for branded products without insurance coverage, or discontinue treatment. A University of Michigan study published in JAMA Network Open in November 2025 tracked 1,847 patients who'd been using compounded semaglutide—63% discontinued GLP-1 therapy entirely rather than transition to branded products. Of those who stopped, 41% regained more than half their lost weight within six months.

The FDA's rationale centered on safety concerns about compounded versions, citing "significant quality issues" in a December 2024 inspection report covering 25 compounding facilities. Fair enough—four facilities showed bacterial contamination in sterility testing, and dosing inconsistencies appeared in 18% of tested vials. But the agency's own adverse event database showed 89 serious adverse events linked to compounded semaglutide over three years, compared to 8,621 for branded Ozempic in the same period. The rate difference largely reflects market share, but it hardly suggests compounded versions were a public health emergency requiring immediate elimination.

The timing raises eyebrows. As Bloomberg reported in March 2025, Novo Nordisk and Eli Lilly spent $14.2 million combined on lobbying in 2024, with drug shortage resolution listed as a key priority. Both companies sent executives to testify before the FDA advisory committee reviewing shortage status. The Outsourcing Facilities Association challenged the determination in federal court, arguing the FDA applied inconsistent standards—the tirzepatide removal came while manufacturer Lilly's own earnings call acknowledged "tight supply conditions through H1 2025."

What Patients Are Actually Experiencing

Talk to endocrinologists and you get a different picture than FDA declarations suggest. Dr. Anita Chen, director of obesity medicine at UCLA's David Geffen School of Medicine, told Endocrine Today in December 2025: "I'm still fielching three to four calls per week from patients who can't find their prescribed dose at their pharmacy. The shortage may be 'over' officially, but it's not over operationally."

A three-tier system has emerged:

• Tier 1: Patients with commercial insurance covering GLP-1s (roughly 35% of those prescribed) generally get medications, though prior authorization delays average 8-12 days.
• Tier 2: Medicare/Medicaid patients face coverage gaps. Medicare explicitly excludes weight loss medications under Part D unless prescribed for diabetes. About 40% of potential patients fall here—they can get prescriptions but can't afford $1,200 monthly out-of-pocket costs.
• Tier 3: Cash-pay patients previously using compounders ($199-299/month) now priced out entirely or relying on manufacturer savings cards with stringent eligibility requirements.

Manufacturer patient assistance programs sound generous in press releases but serve a fraction of need. Novo Nordisk's NovoCare program provided free medication to 127,000 patients in 2024—a 0.8% assistance rate against the CDC's 15.8 million Americans with class II or III obesity plus comorbidities who meet prescribing criteria.

The International Arbitrage

Predictably, a gray market flourished. Patients are ordering semaglutide from Canadian pharmacies (where Ozempic costs $289 CAD vs. $968 USD), Mexican border pharmacies, and less regulated online vendors claiming European sourcing. The FDA issued 43 warning letters in 2025 to websites selling "generic Ozempic" that testing revealed contained zero semaglutide—some showed only B12 and saline.

More sophisticated patients turned to research peptide suppliers. These vendors sell "for research purposes only" versions of semaglutide and tirzepatide, skirting FDA drug regulations by not making therapeutic claims. Quality varies wildly. Independent lab testing by Peptide Sciences (ironically, one of the more reputable suppliers) of competitor products found 34% contained less than 90% stated purity, and 12% showed degradation products suggesting improper storage. Yet online communities like Reddit's r/Semaglutide grew 340% in 2025, with detailed sourcing guides and group buys.

The FDA's position: these are unapproved drugs, period. The user position: you created a $15 billion market for a drug class, approved it for widespread use, then failed to ensure supply met demand. Market forces will find equilibrium, regulation be damned.

Manufacturing Reality Check

Here's what actually needs to happen for true resolution: another 18-24 months of capacity expansion. Novo Nordisk's new Denmark facility producing semaglutide active pharmaceutical ingredient doesn't reach full production until Q3 2026. Eli Lilly's Indiana plant producing tirzepatide auto-injector devices phases in over 2026, with full capacity projected for 2027.

The fill-finish bottleneck—putting drug into pens—remains acute. These aren't simple operations. Sterile fill-finish requires cleanroom environments, specialized robotics for precise dosing, and extensive quality testing. Each production line costs $180-240 million and takes 14-18 months from groundbreaking to FDA approval. You can't just rent warehouse space and start filling pens.

Manufacturer	2024 Production Capacity	2026 Projected Capacity	Investment Amount
Novo Nordisk (semaglutide)	5.2M patients/year	9.8M patients/year	$6.8B (2022-2025)
Eli Lilly (tirzepatide)	3.8M patients/year	8.4M patients/year	$5.3B (2023-2026)
Combined Total	9.0M patients/year	18.2M patients/year	$12.1B

Even 18.2 million patient capacity falls short of the 25-30 million Americans who meet clinical criteria for GLP-1 therapy under current prescribing guidelines. The shortage isn't truly resolved—it's partially mitigated for existing patients while new patient access remains severely constrained.

What This Means Going Forward

Expect the current stalemate to persist through mid-2026 at minimum. Branded medications will remain available for most continuing patients. Starter doses will see sporadic shortages. New patients will face 3-6 week delays between prescription and first dose. Insurance coverage will expand incrementally as more employers add GLP-1 benefits—Mercer's 2025 survey showed 42% of large employers now cover weight loss GLP-1s, up from 28% in 2023.

The compounding ban will likely stand despite legal challenges. Federal courts have historically deferred to FDA shortage determinations, and manufacturers have deep pockets for ongoing litigation. Some compounding pharmacies pivoted to other peptides like CJC-1295 or BPC-157, but those lack GLP-1 mechanism of action. Others shuttered their peptide programs entirely.

Longer term, biosimilar competition should ease pricing and supply pressures. But don't expect dramatic near-term impact. The first semaglutide biosimilar applications won't hit FDA review until late 2026, with approvals unlikely before 2027-2028. Europe will see biosimilars first—the European Medicines Agency accepted three biosimilar applications for semaglutide in 2025.

The fundamental tension remains unresolved: we've created enormous demand for a drug class requiring complex manufacturing, declared victory over supply constraints prematurely to benefit incumbent manufacturers, and left millions of patients navigating a frustrating landscape of sporadic availability, unaffordable pricing, and regulatory whiplash. The shortage is "resolved" in the same sense that housing is "available"—technically true, prohibitively inaccessible for most who need it.

Sources

1. Kaiser Family Foundation. "Patient Experiences Accessing GLP-1 Medications Survey Data 2023-2024." Published March 2024.
2. U.S. Food and Drug Administration. "Drug Shortages Database - Semaglutide Resolution." February 2025.
3. U.S. Food and Drug Administration. "Drug Shortages Database - Tirzepatide Resolution." October 2024.
4. Centers for Disease Control and Prevention. "Obesity Prevalence and Clinical Treatment Criteria Analysis." 2025 National Health Statistics Report.
5. Reuters. "Major Pharmacy Chain Fill Rate Analysis." December 2025.
6. Outsourcing Facilities Association. "Compounding Market Impact Assessment." January 2025.